Education
About Us
Working with TipRanks
Follow Us
X4 Pharmaceuticals Inc (XFOR)
NASDAQ:XFOR
Top Page
X4 Pharmaceuticals
(NASDAQ:XFOR)
57Neutral
Positive Factors
Licensing Agreement
X4 Pharmaceuticals has entered into an exclusive licensing agreement with Norgine Pharmaceuticals for the commercialization of mavorixafor in Europe, Australia, and New Zealand.
Strategic Restructuring
The strategic restructuring, including a reduction in headcount and annual spending, is seen as a prudent measure for long-term growth.
Negative Factors
Commercialization Challenges
The longer-than-expected time to diagnose and initiate therapy for new WHIM patients and the high commercial cost to onboard a patient are challenges faced by the company.
X4 Pharmaceuticals (XFOR) vs. S&P 500 (SPY)
Market Cap
$54.32M
Dividend YieldN/A
Average Volume (3M)4.94M
Price to Earnings (P/E)―
Beta (1Y)2.43
Revenue GrowthN/A
EPS Growth89.36%
CountryUS
Employees93
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.09
Shares Outstanding170,546,460
10 Day Avg. Volume1,601,854
30 Day Avg. Volume4,938,224
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)46.34
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2.17Price Target Upside538.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
X4 Pharmaceuticals Business Overview & Revenue Model
Company DescriptionX4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan and is headquartered in Cambridge, MA.
How the Company Makes MoneyX4 Pharmaceuticals generates revenue primarily through the development and commercialization of its lead product candidates targeting rare diseases. Revenue streams for the company include sales of its approved therapies, royalties from licensing agreements, and potential milestone payments from strategic partnerships with other pharmaceutical companies. By advancing its pipeline of therapeutic candidates through clinical trials, X4 aims to achieve regulatory approvals and market penetration, which would contribute to its revenue growth. Additionally, collaborations and partnerships with larger biotech firms may provide supplemental funding and shared resources, further supporting its financial model.
X4 Pharmaceuticals Financial Statement Overview
Summary
X4 Pharmaceuticals shows initial revenue generation with a strong gross margin, but faces significant net losses and high operational costs. The debt-to-equity ratio indicates moderate leverage risk, which could be problematic if revenues do not stabilize. Despite a solid cash position, persistent losses and reliance on debt financing are concerns.Income Statement
X4 Pharmaceuticals has shown initial revenue generation in TTM with a gross profit margin of 85.19%, which is a positive sign. However, the company continues to experience significant net losses and negative EBIT and EBITDA margins due to high operational costs and R&D investments. The revenue growth from zero in previous years to over $4 million in the TTM is a promising start but is overshadowed by substantial losses.45
Neutral
Balance Sheet
The balance sheet reflects a debt-to-equity ratio of 1.31, indicating moderate leverage which could pose a risk if revenues do not stabilize. The equity ratio stands at 33.47%, showing a reliance on debt financing. Although the company has a solid cash position, continued losses could erode this buffer over time.40
Negative
Cash Flow
Operating cash flow remains negative, reflecting ongoing cash burn typical in biotechnology firms. The free cash flow to net income ratio remains negative. However, financing activities have provided some cash relief, and the free cash flow growth rate shows improvement, indicating better cash management over time.50
Neutral
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 4.18M | 0.00 | 0.00 | 0.00 | 3.00M | 0.00 | Gross Profit |
| 3.56M | -2.00M | -1.99M | -1.89M | 3.00M | -672.00K | EBIT |
| -25.89M | -107.52M | -87.57M | -85.11M | -59.87M | -51.70M | EBITDA |
| -134.66M | -107.10M | -87.57M | -85.11M | -58.06M | -51.70M | Net Income Common Stockholders |
| -16.76M | -101.17M | -93.87M | -88.70M | -62.13M | -56.60M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 78.71M | 114.22M | 121.72M | 81.79M | 78.71M | 126.18M | Total Assets |
| 122.87M | 147.26M | 155.59M | 117.18M | 122.87M | 160.70M | Total Debt |
| 38.45M | 58.28M | 38.42M | 39.78M | 38.45M | 22.91M | Net Debt |
| -40.26M | -40.94M | -83.30M | -42.00M | -40.26M | -103.27M | Total Liabilities |
| 50.07M | 96.16M | 81.53M | 52.76M | 50.07M | 31.48M | Stockholders Equity |
| 72.80M | 51.10M | 74.05M | 64.41M | 72.80M | 129.22M |
| Cash Flow | Free Cash Flow | ||||
| -125.97M | -96.57M | -77.20M | -71.52M | -60.18M | -48.23M | Operating Cash Flow |
| -125.65M | -96.51M | -77.10M | -70.91M | -58.82M | -48.05M | Investing Cash Flow |
| 70.78M | -14.88M | -103.00K | -615.00K | -1.36M | 27.23M | Financing Cash Flow |
| 20.26M | 88.52M | 117.23M | 74.25M | 12.39M | 140.66M |
X4 Pharmaceuticals Technical Analysis
Negative
0.34
Price Trends
0.52
Negative
0.52
Negative
0.63
Negative
Market Momentum
-0.06
Positive
37.26
Neutral
18.30
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XFOR, the sentiment is Negative. The current price of 0.34 is below the 20-day moving average (MA) of 0.41, below the 50-day MA of 0.52, and below the 200-day MA of 0.63, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 37.26 is Neutral, neither overbought nor oversold. The STOCH value of 18.30 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XFOR.
X4 Pharmaceuticals Risk Analysis
X4 Pharmaceuticals disclosed 64 risk factors in its most recent earnings report. X4 Pharmaceuticals reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
X4 Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $125.40B | ― | -3.15% | ― | 11.64% | -114.72% | |
57 Neutral | $54.32M | ― | -26.35% | ― | ― | 89.36% | |
56 Neutral | $1.84B | 2.81 | 57.29% | ― | 36.07% | ― | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
49 Neutral | $30.91B | ― | -414.62% | ― | 22.97% | 38.54% | |
46 Neutral | $3.63B | ― | -19.20% | ― | -89.95% | -123.71% | |
41 Neutral | $62.62M | ― | 41.08% | ― | -0.55% | 49.85% |
* Healthcare Sector Average
Performance Comparison
XFOR
X4 Pharmaceuticals
0.34
-0.50
-59.52%
ALNY
Alnylam Pharma
242.43
93.90
63.22%
VRTX
Vertex Pharmaceuticals
495.42
86.65
21.20%
AGIO
Agios Pharma
31.98
2.52
8.55%
KPTI
Karyopharm Therapeutics
7.53
-12.57
-62.54%
CRSP
Crispr Therapeutics AG
43.49
-28.52
-39.61%
X4 Pharmaceuticals Earnings Call Summary
Earnings Call Date: Nov 13, 2024 | % Change Since: -42.37% | Next Earnings Date: Mar 25, 2025
Earnings Call Sentiment Positive
The earnings call highlighted positive clinical trial results and strategic advancements for X4 Pharmaceuticals, particularly with mavorixafor's potential in chronic neutropenia and the successful launch of XOLREMDI. However, some concerns were noted regarding flat sales and early study discontinuations.Highlights
Positive Phase II Study Results for Mavorixafor in Chronic Neutropenia
The Phase II study showed mavorixafor increased mean absolute neutrophil count (ANC) to normal levels as monotherapy and in combination with G-CSF, with 75% of participants reducing their G-CSF dose.
U.S. FDA Approval and Launch of XOLREMDI
X4 Pharmaceuticals received U.S. FDA approval for XOLREMDI (mavorixafor) for WHIM syndrome, and successfully engaged 3,400 targeted immunologists and hematologists.
Strong Financial Position
X4 Pharmaceuticals ended Q3 2024 with cash and equivalents of $136 million, providing a financial runway into late 2025.
Significant G-CSF Reduction Achieved
In the combination group, G-CSF was reduced by 52% on average at month 3 and 70% at month 6.
High Physician Engagement
75% of surveyed healthcare providers reported they would consider prescribing XOLREMDI for WHIM patients.
Lowlights
Flat Sales of XOLREMDI
Sales of XOLREMDI appeared flat quarter-over-quarter due to initial product stocking in the previous quarter.
Early Phase II Study Discontinuations
Three participants discontinued the Phase II study early due to side effects, though no further discontinuations occurred after implementing an education program.
Company Guidance
During the Q3 2024 earnings call, X4 Pharmaceuticals provided comprehensive guidance on their operational and clinical progress, emphasizing the successful completion of their Phase II study of mavorixafor in chronic neutropenia (CN). The company highlighted the drug's potential as both a monotherapy and in combination with G-CSF, noting that mavorixafor consistently increased absolute neutrophil count (ANC) to clinically meaningful levels, even allowing for a 70% reduction in G-CSF doses in some cases. This Phase II study enrolled 23 participants and demonstrated that mavorixafor was generally well-tolerated. On the commercial front, X4 has engaged with 3,400 immunologists and hematologists to boost awareness of their FDA-approved product XOLREMDI for WHIM syndrome, reporting that 75% of likely prescribers are now knowledgeable about the condition. Financially, X4 ended the quarter with $136 million in cash, projecting a runway into late 2025, excluding anticipated revenue growth from XOLREMDI. The call underscored X4's strategic focus on leveraging existing infrastructure to support potential mavorixafor applications in broader CN indications, with ongoing Phase III trials targeting global patient enrollment across 20-25 countries.X4 Pharmaceuticals Corporate Events
Product-Related AnnouncementsBusiness Operations and Strategy
X4 Pharmaceuticals Partners with Norgine for Mavorixafor Expansion
Positive
Jan 13, 2025
X4 Pharmaceuticals has signed an exclusive licensing and supply agreement with Norgine to commercialize its product mavorixafor in Europe, Australia, and New Zealand. The deal, which includes an upfront payment of €28.5 million and potential milestone payments up to €226 million, allows Norgine to handle market access and commercialization, while X4 focuses on regulatory filings and the ongoing Phase 3 clinical trial. This strategic partnership aims to expand the availability of mavorixafor, a treatment for WHIM syndrome, to new territories and strengthen X4’s financial position.
Product-Related AnnouncementsBusiness Operations and Strategy
X4 Pharmaceuticals: Promising Phase 2 Trial Results
Positive
Nov 13, 2024
X4 Pharmaceuticals has announced promising results from its Phase 2 trial of mavorixafor, an oral treatment for chronic neutropenia. The trial demonstrated that mavorixafor effectively increased mean absolute neutrophil counts (ANC) and allowed for reduced dosing of G-CSF while maintaining normal ANC levels. The findings, including enhanced neutrophil functionality, bolster confidence in the ongoing Phase 3 4WARD trial, offering hope for improved treatments for those with chronic neutropenia.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.